Sponsors (22)
The bill improves diagnosis, treatment, monitoring, and evidence-based claims handling for veterans with blast exposure through VA–DoD coordination and research, but it requires federal resources, could raise benefit costs, and may lose momentum when the temporary Task Force sunsets in 2029 unless sustained support is provided.
Veterans and service members with blast exposure will receive better-tailored clinical care as VA and DoD coordinate research and clinical guidance to recognize and treat blast-related conditions.
VA claims processors and medical examiners will get evidence-based recommendations that can speed and standardize benefits decisions for affected veterans.
Prioritizing translational research (e.g., sleep therapy, gut health, mobile diagnostics, vestibular/autonomic dysregulation, neuroinflammation, cumulative mTBI) and integrating mobile/longitudinal diagnostic tools can accelerate new diagnostics and treatments and improve continuity of care and remote monitoring for veterans.
Establishing and operating the temporary VA–DoD Task Force will incur administrative and coordination costs that require federal resources and may divert VA/DoD capacity or raise taxpayer expense.
Sunsetting the Task Force in 2029 risks losing long-term oversight and research momentum on blast-related conditions unless follow-on programs or funding are created.
If Task Force recommendations lead to broader or more permissive claims evaluation without matched funding, the VA could face increased benefits payouts, budget pressure, and longer waits for veterans.
Based on analysis of 2 sections of legislative text.
Requires VA to create a VA–DoD task force to coordinate research, diagnostics, clinical care, and benefits recommendations for blast overpressure/exposure–related conditions.
Creates a VA-led task force, working through the VA–DoD joint committee, to coordinate research, clinical care, diagnostics, and benefits evaluation for veterans and service members with blast overpressure or blast-exposure–related conditions. The Task Force must be set up within 180 days of enactment, produce annual reports with clinical and research recommendations (including guidance on VA claims and neurological exam practices under 38 U.S.C. chapters 11 and 15), prioritize specific translational research areas, integrate mobile and longitudinal diagnostic tools, and will end on September 30, 2029.
Introduced December 4, 2025 by Ronny Jackson · Last progress December 4, 2025